代谢物的药物相互作用:治疗创新过程中的挑战和解决方案
概括
代谢物介导的药物相互作用 (Met DDIs) 显著影响药物的安全性和有效性. 本综述详细介绍了Met DDI风险评估的监管指南,评估策略和预测建模.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 监管科学 监管科学
背景情况:
- 药物代谢物可以影响药物的有效性和安全性.
- 代谢物介导的药物相互作用 (Met DDIs) 越来越令人担忧,可能导致不良反应和退出市场.
- 世界各地的监管机构越来越多地专注于评估Met DDIs.
研究的目的:
- 审查监管机构关于METDDI的建议.
- 在药物开发过程中概述评估Met DDIs的策略和方法.
- 讨论使用实验室,非临床和临床数据与计算模型预测Met DDIs.
主要方法:
- 对主要当局 (FDA,EMA,NMPA,PMDA,ICH) 的监管指南进行全面分析.
- 翻译评估策略的审查从体外研究到in silico建模 (PBPK/PopPK).
- 审查实例研究,说明Met DDI风险减轻的实际应用和挑战.
主要成果:
- 监管机构在积极的Met DDI风险评估方面达成共识.
- 在指南中发现了范围,门和实施要求的关键差异.
- 一个整合体外,体内和临床数据的翻译策略为Met DDI评估提供了一个强大的框架.
结论:
- 甲基DDI具有重大临床风险,需要进行彻底评估.
- 在全球药物开发中,对Met DDI评估的协调方法至关重要.
- 在经验数据的支持下,先进的建模和模拟对于预测和减轻Met DDI风险至关重要.
相关概念视频
01:27Pharmacogenetics of Drug Metabolism: Overview
87
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
87
01:25Pharmacokinetics: Drug–Drug Interactions
600
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
600
01:30Drug toxicity: Drug–Drug Interaction
223
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
223
01:16Drug Biotransformation: Overview
4.1K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
4.1K
01:28Drug Biotransformation: Overview
4.9K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
4.9K
01:21Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
898
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
898